Peter Collum
Directeur Financier/CFO chez REDX PHARMA PLC
Fortune : 29 040 $ au 30/04/2024
Postes actifs de Peter Collum
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| REDX PHARMA PLC | Directeur Financier/CFO | 05/05/2021 | - |
Historique de carrière de Peter Collum
Anciens postes connus de Peter Collum
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PHARNEXT SCA | Directeur Financier/CFO | 26/06/2019 | 01/04/2021 |
MTS Health Partners LP
 MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/06/2009 | 01/06/2019 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 01/01/2009 | 01/01/2009 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/01/2000 | 01/01/2000 |
Formation de Peter Collum
| Rutgers State University of New Jersey | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
| France | 3 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director of Finance/CFO | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Finance | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| PHARNEXT SCA | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
MTS Health Partners LP
MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Finance |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
- Bourse
- Insiders
- Peter Collum
- Expérience